| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
175,406,000 |
| Market
Cap: |
6.02(B) |
| Last
Volume: |
892,273 |
Avg
Vol: |
2,216,431 |
| 52
Week Range: |
$16.26 - $50.96 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Drug Manufacturers - Major |
|
Member Indexes:
|
| |
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Rigel Pharmaceuticals is a biotechnology company focused on discovering, developing and providing small molecule drugs that improve the lives of patients with hematologic disorders, cancer and rare immune diseases. Co.'s U.S. Food and Drug Administration approved product is TAVALISSE® (fostamatinib disodium hexahydrate) tablets, an oral spleen tyrosine kinase inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The product is also commercially available in Europe, the U.K. (TAVLESSE) and Canada (TAVALISSE) for the treatment of chronic immune thrombocytopenia in adult patients.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
0 |
0 |
19,830 |
| Total Sell Value |
$0 |
$0 |
$0 |
$424,179 |
| Total People Sold |
0 |
0 |
0 |
4 |
| Total Sell Transactions |
0 |
0 |
0 |
8 |
| End Date |
2025-11-16 |
2025-08-15 |
2025-02-14 |
2024-02-15 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Santos David A |
EVP, Chief Commercial Officer |
• – – |
2026-02-10 |
4 |
D |
$34.62 |
$122,763 |
D/D |
(3,546) |
43,440 |
|
- |
|
| Rojkjaer Lisa |
EVP, Chief Medical Officer |
• – – |
2026-02-10 |
4 |
D |
$34.62 |
$130,102 |
D/D |
(3,758) |
15,959 |
|
- |
|
| Furey Raymond J. |
EVP, GC, CCO & Corp Sec |
• – – |
2026-02-10 |
4 |
D |
$34.62 |
$122,763 |
D/D |
(3,546) |
32,316 |
|
- |
|
| Schorno Dean L |
EVP & Chief Financial Officer |
• – – |
2026-02-10 |
4 |
D |
$34.62 |
$122,763 |
D/D |
(3,546) |
55,701 |
|
- |
|
| Rodriguez Raul R |
CEO, President |
• • – |
2026-02-10 |
4 |
D |
$34.62 |
$263,354 |
D/D |
(7,607) |
228,102 |
|
- |
|
| Furey Raymond J. |
EVP, GC, CCO & Corp Sec |
• • – |
2026-02-02 |
4 |
D |
$36.01 |
$142,888 |
D/D |
(3,968) |
35,862 |
|
- |
|
| Rodriguez Raul R |
CEO, President |
• • – |
2026-02-02 |
4 |
D |
$36.01 |
$508,101 |
D/D |
(14,110) |
235,709 |
|
- |
|
| Santos David A |
EVP, Chief Commercial Officer |
• • – |
2026-02-02 |
4 |
D |
$36.01 |
$205,905 |
D/D |
(5,718) |
46,986 |
|
- |
|
| Schorno Dean L |
EVP & Chief Financial Officer |
• • – |
2026-02-02 |
4 |
D |
$36.01 |
$197,623 |
D/D |
(5,488) |
59,247 |
|
- |
|
| Miller Michael Patrick |
|
– • – |
2026-02-01 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
187 |
|
-5% |
|
| Rodriguez Raul R |
CEO, President |
• • – |
2026-01-26 |
4 |
D |
$37.00 |
$2,613,495 |
D/D |
(70,635) |
249,819 |
|
- |
|
| Rodriguez Raul R |
CEO, President |
• • – |
2026-01-26 |
4 |
OE |
$27.40 |
$2,192,000 |
D/D |
80,000 |
285,243 |
|
- |
|
| Schorno Dean L |
EVP & Chief Financial Officer |
• • – |
2025-12-22 |
4 |
OE |
$18.70 |
$139,786 |
D/D |
6,500 |
64,235 |
|
- |
|
| Frohlich Mark W |
|
• • – |
2025-05-23 |
4 |
A |
$0.00 |
$0 |
D/D |
1,250 |
1,250 |
|
- |
|
| Moos Walter H |
|
• • – |
2025-05-23 |
4 |
A |
$0.00 |
$0 |
D/D |
2,500 |
12,722 |
|
- |
|
| Ali-Jackson Kamil |
|
• • – |
2025-05-23 |
4 |
A |
$0.00 |
$0 |
D/D |
2,500 |
9,375 |
|
- |
|
| Hannah Alison L. |
|
• • – |
2025-05-23 |
4 |
A |
$0.00 |
$0 |
D/D |
2,500 |
10,625 |
|
- |
|
| Wasman Jane |
|
• • – |
2025-05-23 |
4 |
A |
$0.00 |
$0 |
D/D |
2,500 |
12,500 |
|
- |
|
| Lapointe Gregg Anthony |
|
• • – |
2025-05-23 |
4 |
A |
$0.00 |
$0 |
D/D |
2,500 |
12,500 |
|
- |
|
| Rodriguez Raul R |
CEO, President |
• • – |
2025-02-05 |
4 |
S |
$21.93 |
$96,474 |
D/D |
(4,400) |
239,454 |
|
11% |
|
| Schorno Dean L |
EVP & Chief Financial Officer |
• • – |
2025-02-05 |
4 |
S |
$21.93 |
$38,020 |
D/D |
(1,734) |
57,235 |
|
11% |
|
| Furey Raymond J. |
EVP, GC, CCO & Corp Sec |
• • – |
2025-02-05 |
4 |
S |
$21.93 |
$29,359 |
D/D |
(1,339) |
38,830 |
|
11% |
|
| Santos David A |
EVP, Chief Commercial Officer |
• • – |
2025-02-05 |
4 |
S |
$21.93 |
$39,379 |
D/D |
(1,796) |
51,704 |
|
11% |
|
| Rodriguez Raul R |
CEO, President |
• • – |
2025-02-04 |
4 |
S |
$20.92 |
$103,601 |
D/D |
(4,952) |
243,854 |
|
2% |
|
| Schorno Dean L |
EVP & Chief Financial Officer |
• • – |
2025-02-04 |
4 |
S |
$20.92 |
$42,595 |
D/D |
(2,036) |
58,969 |
|
2% |
|
104 Records found
|
|
Page 1 of 5 |
|
|
0.10 (0.29%) 
